Staley Capital Advisers Inc. increased its stake in Pharmerica Corporation (NYSE:PMC) by 35.4% during the third quarter, Holdings Channel reports. The firm owned 19,586 shares of the company’s stock after buying an additional 5,121 shares during the period. Staley Capital Advisers Inc. owned about 0.06% of Pharmerica Corporation worth $550,000 at the end of the most recent reporting period.
Several other institutional investors also recently added to or reduced their stakes in the company. Aperio Group LLC bought a new position in Pharmerica Corporation during the third quarter valued at approximately $275,000. First Trust Advisors LP boosted its stake in shares of Pharmerica Corporation by 98.3% in the third quarter. First Trust Advisors LP now owns 35,319 shares of the company’s stock valued at $991,000 after buying an additional 17,512 shares in the last quarter. Nordea Investment Management AB boosted its stake in shares of Pharmerica Corporation by 4.3% in the third quarter. Nordea Investment Management AB now owns 64,900 shares of the company’s stock valued at $1,822,000 after buying an additional 2,700 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Pharmerica Corporation by 32.6% in the third quarter. Wells Fargo & Company MN now owns 408,980 shares of the company’s stock valued at $11,480,000 after buying an additional 100,556 shares in the last quarter. Finally, Peregrine Capital Management LLC acquired a new stake in shares of Pharmerica Corporation during the third quarter valued at $13,041,000. 96.56% of the stock is currently owned by hedge funds and other institutional investors.
Pharmerica Corporation (NYSE:PMC) remained flat at $25.60 on Friday. 36,758 shares of the company’s stock were exchanged. The stock has a market cap of $787.99 million, a price-to-earnings ratio of 23.34 and a beta of 0.97. The stock has a 50 day moving average of $25.60 and a 200 day moving average of $25.51. Pharmerica Corporation has a 12 month low of $19.20 and a 12 month high of $31.02.
Pharmerica Corporation (NYSE:PMC) last issued its quarterly earnings data on Wednesday, November 9th. The company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by $0.07. The firm had revenue of $512.60 million for the quarter, compared to analyst estimates of $530.01 million. Pharmerica Corporation had a return on equity of 10.40% and a net margin of 1.64%. Pharmerica Corporation’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.39 EPS. On average, equities analysts expect that Pharmerica Corporation will post $1.87 EPS for the current year.
Separately, Zacks Investment Research upgraded shares of Pharmerica Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, January 18th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $30.00.
Pharmerica Corporation Company Profile
PharMerica Corporation is an institutional pharmacy services company. The Company services healthcare facilities, provides pharmacy management services to hospitals, provides specialty infusion services to patients outside a hospital setting and offers the national oncology pharmacy in the United States.
Want to see what other hedge funds are holding PMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pharmerica Corporation (NYSE:PMC).